Brief: BioXcel Therapeutics: Topline Data Expected In H2 Of 2025 To Support Potential SNDA Submission For Label Expansion Of Igalmi In Home Setting
11/03/2025 11:04
March 11 (Reuters) - BioXcel Therapeutics Inc BTAI.O: BIOXCEL THERAPEUTICS : TOPLINE DATA EXPECTED IN H2 OF 2025 TO SUPPORT POTENTIAL SNDA SUBMISSION FOR LABEL EXPANSION OF IGALMI IN HOME SETTING Source text: ID:nGNXQGgN9 Further company coverage: BTAI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty